Anthony Fauci

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6159636/publications.pdf

Version: 2024-02-01

26 papers	3,283 citations	361413 20 h-index	552781 26 g-index
26 all docs	26 docs citations	26 times ranked	3783 citing authors

#	Article	IF	Citations
1	Blocking Î± ₄ Î² ₇ integrin delays viral rebound in SHIV _{SF162P3} -infected macaques treated with anti-HIV broadly neutralizing antibodies. Science Translational Medicine, 2021, 13, .	12.4	11
2	Fitting a vaccine into the HIV prevention landscape. Journal of the International AIDS Society, 2021, 24, e25792.	3.0	3
3	The V2 loop of HIV gp120 delivers costimulatory signals to CD4⁺T cells through Integrin Î±₄Î²₇and promotes cellular activation and infection. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32566-32573.	7.1	14
4	Delayed vaginal SHIV infection in VRC01 and anti-Î±4Î²7 treated rhesus macaques. PLoS Pathogens, 2019, 15, e1007776.	4.7	16
5	Evaluation of an antibody to Î± ₄ Î² ₇ in the control of SIVmac239- nef-stop infection. Science, 2019, 365, 1025-1029.	12.6	29
6	An open-label phase 1 clinical trial of the anti-Î± ₄ Î² ₇ monoclonal antibody vedolizumab in HIV-infected individuals. Science Translational Medicine, 2019, 11, .	12.4	40
7	Measles in 2019 â€" Going Backward. New England Journal of Medicine, 2019, 380, 2185-2187.	27.0	127
8	The Role of Integrin Î±4Î²7 in HIV Pathogenesis and Treatment. Current HIV/AIDS Reports, 2018, 15, 127-135.	3.1	36
9	Integrin Î± ₄ Î² ₇ expression on peripheral blood CD4 ⁺ T cells predicts HIV acquisition and disease progression outcomes. Science Translational Medicine, 2018, 10, .	12.4	85
10	Early treatment of SIV+ macaques with an Î±4Î²7 mAb alters virus distribution and preserves CD4+ T cells in later stages of infection. Mucosal Immunology, 2018, 11, 932-946.	6.0	43
11	MAdCAM costimulation through Integrin-Î±4Î²7 promotes HIV replication. Mucosal Immunology, 2018, 11, 1342-1351.	6.0	26
12	Virion incorporation of integrin Î±4Î²7 facilitates HIV-1 infection and intestinal homing. Science Immunology, 2017, 2, .	11.9	49
13	Early antibody therapy can induce long-lasting immunity to SHIV. Nature, 2017, 543, 559-563.	27.8	244
14	A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection. Science Translational Medicine, 2017, 9, .	12.4	105
15	Sustained virologic control in SIV ⁺ macaques after antiretroviral and Î± ₄ Î² ₇ antibody therapy. Science, 2016, 354, 197-202.	12.6	194
16	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. New England Journal of Medicine, 2016, 375, 2037-2050.	27.0	391
17	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206.	12.4	390
18	Species-Specific Differences in the Expression and Regulation of Î±4Î²7 Integrin in Various Nonhuman Primates. Journal of Immunology, 2015, 194, 5968-5979.	0.8	17

#	Article	IF	Citations
19	Targeting Î±4Î²7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nature Medicine, 2014, 20, 1397-1400.	30.7	134
20	HIV reservoirs. Aids, 2012, 26, 1261-1268.	2.2	151
21	The integrin Î± ₄ Î² ₇ forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 20877-20882.	7.1	258
22	HIV-1 envelope protein binds to and signals through integrin Î±4Î²7, the gut mucosal homing receptor for peripheral T cells. Nature Immunology, 2008, 9, 301-309.	14.5	521
23	HIV-1 envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in primary human CD4+ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1178-1183.	7.1	123
24	B cell growth and differentiation factors interact with receptors distinct from the interleukin 2 receptor. European Journal of Immunology, 1986, 16, 761-766.	2.9	11
25	Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis and Rheumatism, 1982, 25, 396-400.	6.7	161
26	Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary sjÃ¶gren's syndrome. Arthritis and Rheumatism, 1981, 24, 577-584.	6.7	104